Stereotaxis Stock
Price
Target price
€1.88
€1.88
-2.190%
-0.04
-2.190%
-
24.06.25 / Tradegate
WKN: A1J09L / Symbol: STXS / Name: Stereotaxis / Stock / Healthcare Equipment & Supplies / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Stereotaxis Stock
A loss of -2.190% shows a downward development for Stereotaxis.
Pros and Cons of Stereotaxis in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Stereotaxis vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stereotaxis | -2.190% | 1.622% | 0.000% | 13.939% | -16.814% | -2.083% | -59.130% |
| Lightpath Techs A | -2.290% | 4.065% | 30.612% | 128.571% | -25.581% | 115.126% | -6.569% |
| Electrocore Inc. | 0.910% | 2.765% | 6.190% | 21.642% | 21.642% | -42.810% | -59.782% |
| Cardiff Oncology Inc. | -0.560% | -0.372% | -2.190% | 22.654% | -35.885% | 27.498% | -40.708% |
News
Stereotaxis Stock: FDA Applications Signal Strategic Pivot
Stereotaxis (NYSE: STXS), a pioneer in robotic technologies for minimally invasive endovascular procedures, has filed regulatory applications with the U.S. Food and Drug Administration for two
